%0 Journal Article
%T Specific association of MTHFD1 expressions with small cell lung cancer development and chemoradiotherapy outcome.
%A Hao Y
%A Lu R
%A Guo Y
%A Bao P
%J Saudi Med J
%V 45
%N 8
%D 2024 Aug
%M 39074897
%F 1.422
%R 10.15537/smj.2024.45.8.20230990
%X <B>OBJECTIVE: </B>To identify biomarkers that can discriminated small cell lung cancer (SCLC) from non-SCLC (NSCLC), and explore their association with the prognosis of SCLC under chemoradiotherapy.<BR><B>METHODS: </B>The GSE40275 dataset was used to identify potential targets in SCLC. There were 196 patients of lung cancer (LC) in cohort 1 of this study. MTHFD1 levels in tissues were determined by immunohistochemistry assay in cohort 1. Lung cancer patients who were all underwent local chemoradiotherapy (CRT) were included in cohort 2, and the association of MTHFD1 levels with CRT treatment outcome were determined in cohort 2. Cell experiments were used to determine the function of MTHFD1 on the radio-sensitivity of SCLC and NSCLC cells.<BR><B>RESULTS: </B>The MTHFD1 levels in LC tissues were increased, and could discriminate SCLC from both lung squamous cell carcinoma (LUSC) and lung adenocarcinoma (LUAD). Small cell lung cancer patients with MTHFD1 high phenotype had a poorer prognosis after CRT treatment, whereas no significant correlation was found between MTHFD1 levels and prognosis in LUSC and LUAD group. Cell experiments demonstrated that overexpression of MTHFD1 increases radio-resistance in both SCLC and NSCLC in vitro.<BR><B>CONCLUSIONS: </B>MTHFD1 expressions might be a novel specifically prognostic biomarker for SCLC and the CRT treatment outcome.